Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets

被引：0
|
作者：
Lovett-Racke, A. [1 ,2 ]
Liu, Y. [2 ]
Gormley, M. [2 ]
Wray, S. [3 ]
Racke, M. [4 ]
Shubin, R. [5 ]
Su, W. [6 ]
Eubanks, J. [6 ]
Fox, E. [7 ]
机构：
[1] Ohio State Univ, Microbial Infect & Immun, Columbus, OH 43210 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Hope Neurol, Knoxville, TN USA
[4] Ohio State Univ, Neurol, Columbus, OH 43210 USA
[5] Arcadia Neurol Ctr, Pasadena, CA USA
[6] TG Therapeut, New York, NY USA
[7] Cent Texas Neurol Consultants, Round Rock, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1158
引用
收藏
页码：609 / 610
页数：2
相关论文
共 39 条
  • [21] A phase 1 trial of BCD-132, a novel anti-CD20 monoclonal antibody, in patients with remitting forms of multiple sclerosis
    Boyko, O.
    Zinkina-Orikhan, A.
    Kotov, S.
    Linkova, Y.
    Prakhova, L.
    Totolyan, N.
    Shur, S.
    Boyko, A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 740 - 741
  • [22] A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients
    Deng, Changchun
    Amengual, Jennifer Effie
    Schreeder, Marshall T.
    Clark-Garvey, Sean
    Patterson, Molly
    Miskin, Hari
    Sportelli, Peter
    O'Connor, Owen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
    Kolibaba, Kathryn
    Burke, John M.
    Brooks, Heather D.
    Mahadevan, Daruka
    Melear, Jason
    Farber, Charles M.
    Fanning, Suzanne R.
    Schreeder, Marshall T.
    Boccia, Ralph V.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Sharman, Jeff P.
    BLOOD, 2015, 126 (23)
  • [24] A phase 2 randomized, double-blinded, placebo-controlled, multicenter study of subcutaneous daclizumab, a humanized anti-CD-25 monoclonal antibody, in patients with active, relapsing forms of multiple sclerosis - Week 44 results
    Kaufman, Michael D.
    Wynn, Daniel R.
    Montalban, Xavier
    Wang, Min
    Fong, Alice
    NEUROLOGY, 2008, 70 (11) : A220 - A220
  • [25] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    BLOOD, 2012, 119 (22) : 5126 - 5132
  • [26] FINAL RESULTS OF A MULTICENTER PHASE IB SINGLE AGENT STUDY WITH THE NOVEL ANTI-CD20 MONOCLONAL ANTIBODY UBLITUXIMAB (TG-1101) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Cazin, B.
    Lepretre, S.
    Coiffier, B.
    Aurran, T.
    Cartron, G.
    Feugier, P.
    Brehar, O.
    Sadoun, A.
    Sportelli, P.
    Miskin, H.
    Ribrag, V.
    HAEMATOLOGICA, 2013, 98 : 47 - 47
  • [27] A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
    Sawas, Ahmed
    Farber, Charles M.
    Schreeder, Marshall T.
    Khalil, Mazen Y.
    Mahadevan, Daruka
    Deng, Changchun
    Amengual, Jennifer E.
    Nikolinakos, Petros G.
    Kolesar, Jill M.
    Kuhn, John G.
    Sportelli, Peter
    Miskin, Hari P.
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) : 243 - 253
  • [28] Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study
    Xu, Min
    Shu, Jinhui
    Qian, Shenxian
    Guo, Jingming
    Gong, Yuping
    Huang, Ruibin
    Wang, Shuye
    Zhou, Zeping
    Yuan, Guolin
    Huang, Meijuan
    Lin, Li -E
    Lou, Shifeng
    Song, Yanping
    Liu, Qingchi
    Zhou, Hu
    Mei, Heng
    Hu, Yu
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 47
  • [29] Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
    Shi, Y-K.
    Song, Y.
    Qin, Y.
    Zhou, K.
    Gao, Y.
    Wang, M.
    Wang, P.
    Yin, Q.
    Zhao, F.
    Ma, G.
    Li, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
  • [30] Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
    Agius, Mark A.
    Klodowska-Duda, Gabriela
    Maciejowski, Maciej
    Potemkowski, Andrzej
    Li, Jing
    Patra, Kaushik
    Wesley, Jacob
    Madani, Soraya
    Barron, Gerard
    Katz, Eliezer
    Flor, Armando
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (02) : 235 - 245
1234